Author

J. Mudd

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Adonyi· 1 shared A. Dhanasopon· 1 shared A. K. Palucka· 1 shared A. Oyedeji· 1 shared A. Saied· 1 shared B. Judson· 1 shared B. Krasnick· 1 shared C. Coyne· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Adonyi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Immune Correlates of Hyperglycemia and Vaccination in a Non-human Primate Model of Long-COVID

C. S. Palmer, C. Perdios, M. Abdel-Mohsen, J. Mudd, P. Datta, N. Maness, G. Lehmicke, N. Golden, L. Hellmer, C. Coyne, K. Moore Green, C. Midkiff, K. Williams, R. Tiburcio, M. Fahlberg, , J. Rappaport

This study establishes a non-human primate model of metabolic PASC, identifies immune correlates of hyperglycemia, and shows vaccine-induced glycemic improvement.

bioRxiv · Sep 22, 2023 · PreprintImmunology

Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment

M. Chiorazzi, J. Martinek, B. Krasnick, Y. Zheng, K. J. Robbins, R. Qu, G. Kaufmann, Z. Skidmore, L. A. Henze, F. Brosecke, A. Adonyi, J. Zhao, L. Shan, E. Sefik, J. Mudd, , R. A. Flavell

This study develops an autologous humanized PDX model to study tumor-immune interactions and demonstrates its utility in preclinical testing by showing VEGF-A inhibition reduces tumor growth.

bioRxiv · Aug 19, 2022 · PreprintCancer Biology